| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
The 8th edition AJCC/UICC TNM staging is effective for HPV-related oropharyngeal squamous cell carcinoma (OPSCC) after January 1,2017. We retrospectively analyzed 175 patients with OPSCC treated in Hokkaido University Hospital between 1998 and 2014. Of the 152 OPSCC patients, 83 (47.4%) were positive for HPV, and 92 (52.6%) were negative. 3-year overall survival rate was significantly lower in the HPV-negative patients with stage III and IV as compared with stage I and II. 3-year overall survival rate was not significantly different between stage I-III versus stage IV . According to 8th edition AJCC/UICC TNM staging system, 3-year overall survival rate was relatively distinguishable between stage I-II and III. The 7th edition AJCC/UICC TNM staging system is acceptable for HPV-negative patients, however, unsuitable for HPV-positive patients. The 8th edition AJCC/UICC TNM staging system is suitable for HPV-related OPSCC in Japan.
|
